You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Center for Human Genetics and Laboratory Medicine's Prenatalis test is based on Illumina's Verifi technology.
Birmingham Women's NHS Foundation Trust said it is partnering with Illumina to develop an NIPT, which it hopes to start offering in September.
SeraCare is licensing UCSF's T21, T18, and T13 trophoblast cell line materials to develop NIPT reference materials.
Non-invasive prenatal screening tests are not only detecting fetal chromosomal abnormalities, but also some cases of maternal cancer.
The results are the most comprehensive picture so far of the patterns of abnormal NIPT results that could indicate a woman has a higher risk of carrying an unknown tumor.
The company's new clinical laboratory will provide interim and backup services for its customers.
The firm said in an SEC document that it plans to offer 6.25 million shares and expects net proceeds of up to $103.3 million.
The UK NIPT firm said that is creating a provision of £500,000 to cover expected expenses related to litigation involving Illumina.
The partners will leverage IME's rare cell isolation technology, a microchip containing a microfabricated filter membrane to isolate and enrich fetal cells from maternal blood.
Patent law experts said the ruling provides further clarity over what is and is not patentable within the broader molecular diagnostics field.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.